January 31, 2026 (Global) – Haemonetics Corporation (NYSE: HAE) has sparked renewed investor confidence following its acquisition of Vivasure Medical, reinforcing its strategic position in advanced medical technology and vessel closure solutions. The move has drawn positive analyst attention and contributed to a broader bullish sentiment around the company’s growth outlook.
The acquisition of Vivasure Medical — a Galway, Ireland-based developer of next-generation percutaneous vessel closure systems — expands Haemonetics’ portfolio with innovative, bioabsorbable vascular closure technology designed to streamline structural heart and endovascular procedures. The deal underscores Haemonetics’ commitment to enhancing patient outcomes and diversifying its offerings across key interventional markets.
“We continue to see Haemonetics’ strategic growth initiatives as a key driver for long-term shareholder value,” said Michael Petusky of Barrington Research, maintaining his *Outperform* rating on HAE and increasing the price target to $93. This reflects a strong endorsement from the investment community following the Vivasure acquisition.
Strategic Impact and Outlook
- Strengthened Technology Portfolio: The addition of Vivasure’s PerQseal® Elite system — a sutureless, fully absorbable device for large-bore arterial and venous closure — positions Haemonetics for expanded leadership in fast-growing interventional procedure markets.
- Analyst Confidence: Multiple analysts have reaffirmed positive ratings on HAE shares, with revised price targets reflecting upside potential tied to the company’s expanding capabilities and strategic direction.
- Investor Sentiment: Haemonetics’ acquisition is seen as a catalyst for improved market confidence, reinforcing its role in delivering innovative solutions in blood management and vascular technologies.
Industry observers note that this acquisition aligns with broader trends in medical devices, where technological differentiation and clinical value are key drivers of long-term growth and shareholder appeal.
